Protecting Intellectual Property in AI Drug Discovery

The IP Landscape in AI Drug Discovery

Drug discovery generates multiple forms of valuable intellectual property:

• Target hypotheses: Which biological targets might be therapeutically relevant
• Structural insights: Protein structures, binding sites, druggability assessments
• Molecular designs: Novel compounds, peptides, or protein binders
• SAR data: Structure-activity relationships from screening and optimization
• Discovery strategies: Workflows, prioritization criteria, decision frameworks

When this information is processed through AI platforms, organizations must understand how their data is handled, stored, and potentially used.

Key IP Protection Considerations

Data Ownership and Rights

Contractual clarity on data ownership is fundamental. Key questions include:

• Who owns the input data (targets, sequences, structures)?
• Who owns the output data (predictions, designs, analyses)?
• Are there any licenses granted to the platform vendor?
• Can the organization freely use outputs for patent filings?

Model Training and Data Usage

Some AI platforms use customer data to train or improve their models. This raises important questions:

• Is customer data used for model training?
• If so, does this create any IP exposure?
• Can training data usage be excluded contractually?
• How is data anonymized or aggregated if used?

Data Storage and Access

Understanding where data resides and who can access it is essential:

• Where is data stored geographically?
• Who has access to customer data within the vendor organization?
• What security controls protect data at rest and in transit?
• How is data isolated in multi-tenant environments?
• What happens to data when the contract ends?

Infrastructure Control as IP Protection

Deployment model directly affects data control:

Vendor-Hosted Platforms

Data is processed on vendor infrastructure. Protection depends primarily on contractual terms and vendor security practices. Organizations have limited technical control over data handling.

Private Cloud Deployment

Data remains within organizational cloud accounts. The organization controls access, encryption, and audit logging. Vendor accesses the environment for software operation but doesn't have custody of data.

On-Premise Deployment

Data never leaves organizational facilities. Maximum technical control over data handling. Can operate in air-gapped environments for highest-sensitivity research.

Contractual Protections

Legal agreements should clearly address:

Confidentiality

• Definition of confidential information
• Vendor obligations to protect confidential data
• Restrictions on disclosure to third parties
• Duration of confidentiality obligations

Data Usage Rights

• Explicit statement that customer owns customer data
• Limitations on vendor use of customer data
• Exclusion from model training if desired
• Rights to outputs and derived insights

Security and Compliance

• Security certifications and audit rights
• Breach notification requirements
• Data retention and deletion terms
• Compliance with relevant regulations

Operational Best Practices

Data Classification

Not all data requires the same protection level. Classify research data by sensitivity and apply appropriate handling:

• Highly sensitive: Late-stage programs, near-IND data, competitive advantages
• Moderately sensitive: Early discovery, exploratory research
• Low sensitivity: Public domain information, published structures

Platform Selection by Sensitivity

Match deployment model to data sensitivity. Organizations might use vendor-hosted platforms for low-sensitivity exploratory work while reserving on-premise deployment for crown-jewel programs.

Access Management

Control who can submit data to external platforms. Implement review processes for highly sensitive projects. Maintain records of what data has been processed where.

Output Review

Review platform outputs before incorporating into patent applications or public disclosures. Understand any limitations on claiming computational predictions.

Evolving Considerations

The intersection of AI and IP in drug discovery continues to evolve:

• AI-generated inventions: Legal frameworks for AI contributions to patentable inventions remain unsettled
• Training data provenance: Questions about what data AI models were trained on may become more important
• Regulatory expectations: Regulatory agencies may develop specific expectations for AI-assisted discovery